Project Grant R01CA315333
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $602K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Grant Award Summary Baylor College of Medicine received a $160,500 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective July 10, 2025, with completion targeted for June 30, 2027. The award funds the development and investigation of in vivo murine models to examine the role of caspase-2 in nucleophosmin-mutated acute myeloid leukemia (NPM1C+ AML). The research deliverables include the establishment of transgenic mouse...
- The National Cancer Institute awarded Baylor College of Medicine $108,214 under the Cancer Research Manpower program (CFDA 93.398) on December 1, 2026. The project investigates post-transcriptional regulation as a therapeutic vulnerability in acute myeloid leukemia. The work tests the hypothesis that EIF4A1 inhibition is an effective AML therapy capable of overcoming menin inhibitor resistance. Aim 1 involves generating novel mouse models of menin inhibitor-resistant adult and pediatric AML to...
- The National Institute of General Medical Sciences awarded $421,250 to H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support research on regulation of selenium metabolism and selenoprotein synthesis. The project will investigate how distinct dietary forms of selenium are absorbed and distributed in the body, how tissues prioritize selenium use under limiting conditions, and how...
- Federal Grant Award Summary Baylor College of Medicine received a $2.4 million Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective August 15, 2025 through July 31, 2029. The award funds research investigating the role of RNA sequestration in acute myeloid leukemia (AML), specifically examining how the RNA helicase DDX6 (DEAD-Box Helicase 6) regulates post-transcriptional processes critical to leukemia development and...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $621,632 on June 17, 2026, under the Cancer Treatment Research program (CFDA 93.395) to elucidate the molecular and metabolic mechanisms underlying disulfidptosis and therapeutically target this form of regulated cell death in SLC7A11-high cancers. The research employs human cancer cell lines and integrated cell-based molecular analyses including metabolomics, proteomics, CRISPR screening, and biochemical...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $429,471 to the University of Texas at Austin on August 26, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research on therapeutic targeting of mitochondrial oxidative phosphorylation (OXPHOS) and lipid remodeling in relapsed acute myeloid leukemia (AML). The award funds investigation of metabolic vulnerabilities in venetoclax-resistant AML cells. The research explores...
- The National Institutes of Health National Cancer Institute awarded The University of Texas Southwestern Medical Center $688,012 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop novel RPS23 inhibitors for the treatment of acute myeloid leukemia. The funded research develops ligands that bind the ribosomal protein RPS23 and activate the integrated stress response through the GCN2 kinase pathway, triggering apoptosis in leukemia cells. The investigator-led...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to investigate combination approaches to acute myeloid leukemia targeting both CD123-directed NK cell engagers and BCL-2 inhibition through venetoclax. The research will employ dynamic BH3 profiling to probe mitochondrial priming mechanisms and test whether...
- The National Cancer Institute awarded Cincinnati Children's Hospital Medical Center $533,245 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop strategies to eradicate leukemia-initiating cells through investigation of protein glutathionylation regulation. The award supports research examining how post-translational modification of proteins through glutathionylation regulates oxidative phosphorylation in acute myeloid leukemia cells and leukemia-initiating cells,...
- The National Cancer Institute awarded Northwestern University $593,307 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate molecular mechanisms underlying nucleophosmin 1 (NPM1)-driven acute myeloid leukemia leukemogenesis. The funded research examines how NPM1 cytoplasmic mutations (NPM1c), which occur in approximately 30 percent of adult de novo AML cases, cooperate with clonal hematopoiesis mutations in DNMT3A, TET2, or IDH1/2 to promote leukemic...